[{"id":"61649098-7ef6-4a13-80de-89bda601b206","acronym":"","url":"https://clinicaltrials.gov/study/NCT05916443","created_at":"2023-06-23T13:09:24.855Z","updated_at":"2024-07-02T16:35:42.210Z","phase":"","brief_title":"Dissecting the Biology of Early-onset Colorectal Cancer","source_id_and_acronym":"NCT05916443","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CD44 • CD24","pipe":" | ","alterations":" CD33 positive • CD44 expression • CD133 positive","tags":["CD44 • CD24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive • CD44 expression • CD133 positive"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-07-24"},{"id":"da006f8e-57f2-49ab-a036-89480d8dec57","acronym":"","url":"https://clinicaltrials.gov/study/NCT02448225","created_at":"2021-01-18T11:43:54.285Z","updated_at":"2024-07-02T16:36:02.214Z","phase":"Phase 2","brief_title":"18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules","source_id_and_acronym":"NCT02448225","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" CD44","pipe":" | ","alterations":" CD44 expression","tags":["CD44"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 06/16/2015","start_date":" 06/16/2015","primary_txt":" Primary completion: 08/02/2021","primary_completion_date":" 08/02/2021","study_txt":" Completion: 10/10/2022","study_completion_date":" 10/10/2022","last_update_posted":"2022-10-19"},{"id":"1e224f1e-e84d-4899-b75d-1b6cfb6c01ea","acronym":"ONAWA","url":"https://clinicaltrials.gov/study/NCT04142892","created_at":"2021-01-18T20:13:20.240Z","updated_at":"2024-07-02T16:36:14.253Z","phase":"Phase 1","brief_title":"Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer","source_id_and_acronym":"NCT04142892 - ONAWA","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • CD24 • ALDH1A1","pipe":" | ","alterations":" ER positive • HER-2 negative • CD44 expression • PGR expression","tags":["HER-2 • ER • CD24 • ALDH1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CD44 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Apristor (onapristone XR)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 04/30/2021","study_completion_date":" 04/30/2021","last_update_posted":"2022-04-01"},{"id":"7258c8df-7d2c-4de0-be2c-bc797c2092c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137653","created_at":"2021-01-18T20:12:26.059Z","updated_at":"2024-07-02T16:36:27.730Z","phase":"Phase 3","brief_title":"Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT","source_id_and_acronym":"NCT04137653","lead_sponsor":"Shengjing Hospital","biomarkers":" ER • PGR • CD44 • CD24","pipe":" | ","alterations":" CD44 expression","tags":["ER • PGR • CD44 • CD24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 1498","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2021-07-20"},{"id":"8ecd0d5a-4acf-4233-aeb0-ac0394f32647","acronym":"","url":"https://clinicaltrials.gov/study/NCT04430595","created_at":"2021-01-18T21:20:15.327Z","updated_at":"2024-07-02T16:36:44.254Z","phase":"Phase 1/2","brief_title":"Multi-4SCAR-T Therapy Targeting Breast Cancer","source_id_and_acronym":"NCT04430595","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression • CD44 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CD44 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 06/01/2020","start_date":" 06/01/2020","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-06-12"},{"id":"0c5c48ba-d7d3-4f6f-bfea-aa634fc92bbd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04137627","created_at":"2021-01-18T20:12:25.557Z","updated_at":"2024-07-02T16:36:52.790Z","phase":"Phase 3","brief_title":"Melatonin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma","source_id_and_acronym":"NCT04137627","lead_sponsor":"Indonesia University","biomarkers":" HIF1A • CD44","pipe":" | ","alterations":" CD44 expression • CD133 expression • HIF1A expression","tags":["HIF1A • CD44"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression • CD133 expression • HIF1A expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 07/04/2017","start_date":" 07/04/2017","primary_txt":" Primary completion: 07/30/2018","primary_completion_date":" 07/30/2018","study_txt":" Completion: 12/18/2018","study_completion_date":" 12/18/2018","last_update_posted":"2019-12-09"},{"id":"d5b00031-1c74-436c-b148-c2ff924d0f5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01688609","created_at":"2021-01-18T07:19:33.354Z","updated_at":"2024-07-02T16:37:18.080Z","phase":"Phase 2","brief_title":"Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer","source_id_and_acronym":"NCT01688609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ALDH1A1","pipe":" | ","alterations":" EGFR mutation • HER-2 overexpression • HER-2 amplification • CD44 expression","tags":["EGFR • HER-2 • ALDH1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • HER-2 overexpression • HER-2 amplification • CD44 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • paclitaxel • lapatinib"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 12/01/2013","primary_completion_date":" 12/01/2013","study_txt":" Completion: 08/15/2016","study_completion_date":" 08/15/2016","last_update_posted":"2017-09-11"},{"id":"b2122966-af02-429e-8475-b26ea7a6cadb","acronym":"","url":"https://clinicaltrials.gov/study/NCT01358903","created_at":"2021-01-18T05:33:37.396Z","updated_at":"2024-07-02T16:37:27.969Z","phase":"Phase 1","brief_title":"A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors","source_id_and_acronym":"NCT01358903","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD44","pipe":" | ","alterations":" CD44 expression","tags":["CD44"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD44 expression"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 06/01/2011","start_date":" 06/01/2011","primary_txt":" Primary completion: 03/01/2014","primary_completion_date":" 03/01/2014","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2016-11-02"}]